Orexo (C5G) Stock Overview
A specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
C5G Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Orexo AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.81 |
| 52 Week High | SEK 3.83 |
| 52 Week Low | SEK 1.09 |
| Beta | 0.90 |
| 1 Month Change | 12.18% |
| 3 Month Change | 11.51% |
| 1 Year Change | 73.24% |
| 3 Year Change | 80.82% |
| 5 Year Change | -42.83% |
| Change since IPO | -52.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| C5G | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.6% | 1.9% | -1.4% |
| 1Y | 73.2% | 18.3% | 10.0% |
Return vs Industry: C5G exceeded the German Pharmaceuticals industry which returned 14.5% over the past year.
Return vs Market: C5G exceeded the German Market which returned 8.9% over the past year.
Price Volatility
| C5G volatility | |
|---|---|
| C5G Average Weekly Movement | 12.2% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: C5G's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: C5G's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 104 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis.
Orexo AB (publ) Fundamentals Summary
| C5G fundamental statistics | |
|---|---|
| Market cap | €100.40m |
| Earnings (TTM) | -€19.06m |
| Revenue (TTM) | €51.34m |
Is C5G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C5G income statement (TTM) | |
|---|---|
| Revenue | SEK 543.50m |
| Cost of Revenue | SEK 58.70m |
| Gross Profit | SEK 484.80m |
| Other Expenses | SEK 686.60m |
| Earnings | -SEK 201.80m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 05, 2026
| Earnings per share (EPS) | -5.85 |
| Gross Margin | 89.20% |
| Net Profit Margin | -37.13% |
| Debt/Equity Ratio | -210.6% |
How did C5G perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/22 10:57 |
| End of Day Share Price | 2026/01/22 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Orexo AB (publ) is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |